Trial Profile
Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2017 Results of proteomic analysis of sera collected from two phase II trial including this published in The Journal of Rheumatology
- 05 Dec 2015 New trial record
- 01 Jan 2015 Status changed from active, no longer recruiting to completed according to results published in the Arthritis and Therapy.